CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity
about
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotesMapping paths: new approaches to dissect eukaryotic signaling circuitryRecent Advances in Genome Editing Using CRISPR/Cas9Genome Engineering with TALE and CRISPR Systems in NeuroscienceThe therapeutic potential of genome editing for β-thalassemiaNuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome EditingTowards a new era in medicine: therapeutic genome editingBeyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogationHow specific is CRISPR/Cas9 really?Minimizing off-Target Mutagenesis Risks Caused by Programmable NucleasesFrom Gene Targeting to Genome Editing: Transgenic animals applications and beyondCRISPR-Cas9: A Revolutionary Tool for Cancer ModellingDesigned nucleases for targeted genome editingA CRISPR method for genome engineeringMaking designer mutants in model organismsMeasuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9Quantifying on- and off-target genome editingSynthetic RNAs for Gene Regulation: Design Principles and Computational ToolsBiased and Unbiased Methods for the Detection of Off-Target Cleavage by CRISPR/Cas9: An OverviewThe application of genome editing in studying hearing lossThe CRISPR system can correct or modify the expression of genes responsible for hereditary diseasesEngineering T Cells to Functionally Cure HIV-1 InfectionCRISPR/Cas9 allows efficient and complete knock-in of a destabilization domain-tagged essential protein in a human cell line, allowing rapid knockdown of protein functionPrecise gene modification mediated by TALEN and single-stranded oligodeoxynucleotides in human cellsCCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infectionA Biophysical Model of CRISPR/Cas9 Activity for Rational Design of Genome Editing and Gene RegulationResources for functional genomics studies in Drosophila melanogasterCHOPCHOP v2: a web tool for the next generation of CRISPR genome engineeringFusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modificationCRISPR-Cas systems for editing, regulating and targeting genomesIn vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle deliveryCas9-based genome editing in Xenopus tropicalis.megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editingAn improved Red/ET recombineering system and mouse ES cells culture conditions for the generation of targeted mutant mice.Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screensHighly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.CRISPR/Cas-mediated targeted mutagenesis in Daphnia magnaBiallelic genome modification in F(0) Xenopus tropicalis embryos using the CRISPR/Cas system.High-efficiency genome editing via 2A-coupled co-expression of fluorescent proteins and zinc finger nucleases or CRISPR/Cas9 nickase pairs
P2860
Q22337358-4AADD22B-F47A-4568-8C6A-238849587BF7Q26740311-9680DC6C-8CDB-4D3C-A688-DABB34B1B3B5Q26744073-709A4228-3F98-4DC3-B956-614807CF4644Q26752488-722165F0-1B72-400E-A4AA-D1C15C5D253AQ26766232-B32578B5-6944-4CA3-8F3B-125D7A980F0BQ26770012-90E50717-75B2-41D6-8C1B-92F0C5428716Q26773287-6B7ACE7E-AC14-464C-B88F-E4D75644EBCBQ26775746-F99BA5B4-153B-47FB-BFC4-D41C7471C528Q26777801-6E0F1730-BCBE-4F27-BA99-7CEFFD944512Q26778992-4BF5293C-BF6B-47B1-8531-624C2ED127D9Q26781859-FB60081C-C105-4E2E-88EF-F746EF871684Q26782773-9FD9AF7C-BD5F-4013-877B-C436AD04C595Q26787105-45428AAB-DDF9-4CA0-AF23-E1EB768E3ABCQ27000786-550CE555-F733-4652-B149-93371136B14CQ27010108-FE3C27A4-2BFC-4FF1-ABA3-DBFF068EDB86Q27011906-1863CFA8-3DE5-4F5C-8EAD-C41FD70C33B4Q27015049-F0ABF0A6-E842-4330-A5C7-406C467809EDQ27694764-B2AD54BF-1EB2-41A6-86C6-FBBC22C09E19Q28069780-F9C1C2DF-E5E9-4B11-B966-678341A92345Q28081706-C44C6A6F-05C4-4ED6-A4C2-6046CFB50BE1Q28085767-BA3800FC-D6E7-4BE0-8AF9-67626E0561DAQ28086801-4F5369C4-EA3B-4538-AD9D-B97D0B7CA405Q28538004-7744AF35-BEB0-4E1C-A509-3349401753E0Q28541724-D6F5C182-6B2B-4FE7-A067-7594660D9E50Q28542878-52C4F08C-44BF-40C9-AFFE-11823422943CQ28552981-802B46E5-B6A4-44A9-8107-A9D236F53BBFQ28657863-E2145490-957A-4F0E-8882-756C76D661FFQ28830073-495E78E8-A310-40AE-9D53-22D73DDC42B2Q29029259-5520A3E6-719E-4644-B27F-81E71AF0F1B0Q29615781-6369BB36-284D-462B-B986-081AD858D38FQ30051830-E3D7D3E8-1AAE-415F-8C77-1E117D57BD45Q30301361-F48F9FA7-614E-46A6-A3DC-BB5836692CC2Q30572833-6E431662-F651-4BC0-814D-13F278AF532DQ30855717-17E292CA-BDA0-4F8B-AF3E-D18D131911DCQ33621571-8E1F8DC2-51D3-493E-85C5-F2E8A8B1FBEEQ33654299-50476650-8475-42E7-9111-142700B131ABQ33657682-B4684001-1E59-4CD3-987E-0339CDEFDC9AQ33690167-4E4891AA-7ED9-405A-855B-73DE1B096E83Q33690341-84BFC9AF-DE48-4889-888C-BDDF2112D549Q33698508-17BB6DF4-B47F-461D-B735-78141682F786
P2860
CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CRISPR/Cas9 systems targeting ...... ubstantial off-target activity
@en
CRISPR/Cas9 systems targeting ...... bstantial off-target activity.
@nl
type
label
CRISPR/Cas9 systems targeting ...... ubstantial off-target activity
@en
CRISPR/Cas9 systems targeting ...... bstantial off-target activity.
@nl
prefLabel
CRISPR/Cas9 systems targeting ...... ubstantial off-target activity
@en
CRISPR/Cas9 systems targeting ...... bstantial off-target activity.
@nl
P2860
P356
P1476
CRISPR/Cas9 systems targeting ...... ubstantial off-target activity
@en
P2093
Christopher J Antico
P2860
P304
P356
10.1093/NAR/GKT714
P407
P577
2013-08-11T00:00:00Z